These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 24472538

  • 1. Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition.
    Jin HO, Lee YH, Park JA, Kim JH, Hong SE, Kim HA, Kim EK, Noh WC, Kim BH, Ye SK, Chang YH, Hong SI, Hong YJ, Park IC, Lee JK.
    Biochem Biophys Res Commun; 2014 Feb 21; 444(4):502-8. PubMed ID: 24472538
    [Abstract] [Full Text] [Related]

  • 2. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY, Wu HC, Wu JE, Huang KY, Yang SC, Chen SX, Tsao CJ, Hsu KF, Chen YL, Hong TM.
    J Exp Clin Cancer Res; 2019 Jul 01; 38(1):282. PubMed ID: 31262325
    [Abstract] [Full Text] [Related]

  • 3. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T, Bellio M, Gentilin E, Molè D, Tagliati F, Schiavon M, Cavallesco NG, Andriolo LG, Ambrosio MR, Rea F, Degli Uberti E, Zatelli MC.
    Endocr Relat Cancer; 2013 Aug 01; 20(4):463-75. PubMed ID: 23653462
    [Abstract] [Full Text] [Related]

  • 4. The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines.
    Herrera VA, Zeindl-Eberhart E, Jung A, Huber RM, Bergner A.
    Anticancer Res; 2011 Mar 01; 31(3):849-54. PubMed ID: 21498705
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H, Jin X, Zhang Z, Xing Y, Kong X.
    Cell Biochem Funct; 2013 Jul 01; 31(5):427-33. PubMed ID: 23086777
    [Abstract] [Full Text] [Related]

  • 6. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS.
    Leuk Res; 2012 Jul 01; 36(7):912-20. PubMed ID: 22560334
    [Abstract] [Full Text] [Related]

  • 7. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC, Yeh HH, Huang WL, Yan JJ, Lai WW, Su WP, Chen HH, Su WC.
    Am J Respir Cell Mol Biol; 2013 Aug 01; 49(2):241-50. PubMed ID: 23526220
    [Abstract] [Full Text] [Related]

  • 8. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A, Lee JE, Lee SS, Kim C, Lee SJ, Jang WS, Park S.
    Int J Cancer; 2013 Aug 15; 133(4):984-96. PubMed ID: 23475782
    [Abstract] [Full Text] [Related]

  • 9. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM, Wozniak A.
    Clin Lung Cancer; 2013 Jul 15; 14(4):322-32. PubMed ID: 23332287
    [Abstract] [Full Text] [Related]

  • 10. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A, Li H, Li R, Lu L, Wu X.
    Oncol Rep; 2018 Oct 15; 40(4):2353-2362. PubMed ID: 30066933
    [Abstract] [Full Text] [Related]

  • 11. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP, Reynolds CP, Kang MH.
    Clin Cancer Res; 2016 Feb 01; 22(3):621-32. PubMed ID: 26080839
    [Abstract] [Full Text] [Related]

  • 12. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
    Brünner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, Valent P, Berger W, Marian B, Zielinski CC, Grusch M, Grunt TW.
    Breast Cancer Res Treat; 2011 Sep 01; 129(2):387-400. PubMed ID: 21046231
    [Abstract] [Full Text] [Related]

  • 13. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D, Lin X, Zhang C, Liu Z, Chen Z, Li Z, Wang J, Li B, Hu Y, Dong B, Shen L, Ji J, Gao J, Zhang X.
    Cell Death Dis; 2018 Jan 26; 9(2):123. PubMed ID: 29374144
    [Abstract] [Full Text] [Related]

  • 14. Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines.
    Katanasaka Y, Kodera Y, Yunokawa M, Kitamura Y, Tamura T, Koizumi F.
    Cancer Lett; 2014 Jun 01; 347(2):196-203. PubMed ID: 24614285
    [Abstract] [Full Text] [Related]

  • 15. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
    Piao J, Chen L, Quan T, Li L, Quan C, Piao Y, Jin T, Lin Z.
    Oncotarget; 2016 Sep 13; 7(37):60169-60180. PubMed ID: 27507059
    [Abstract] [Full Text] [Related]

  • 16. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V.
    Clin Cancer Res; 2011 Aug 15; 17(16):5322-32. PubMed ID: 21712451
    [Abstract] [Full Text] [Related]

  • 17. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
    Xiao P, Sun LL, Wang J, Han RL, Ma Q, Zhong DS.
    Acta Pharmacol Sin; 2015 Sep 15; 36(9):1107-12. PubMed ID: 26027660
    [Abstract] [Full Text] [Related]

  • 18. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D.
    Clin Cancer Res; 2010 Nov 15; 16(22):5424-35. PubMed ID: 20884625
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
    Qian XJ, Li YT, Yu Y, Yang F, Deng R, Ji J, Jiao L, Li X, Wu RY, Chen WD, Feng GK, Zhu XF.
    Oncotarget; 2015 Mar 10; 6(7):5134-46. PubMed ID: 25762617
    [Abstract] [Full Text] [Related]

  • 20. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
    Chang Z, Shi G, Jin J, Guo H, Guo X, Luo F, Song Y, Jia X.
    Int J Mol Med; 2013 Jun 10; 31(6):1449-56. PubMed ID: 23588698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.